Consensus Xencor, Inc.

Stocks

XNCR

US98401F1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-07 EDT			5-day change	1st Jan Change
15.67 ^USD	+5.24%		-2.67%	+2.35%

05-13	Xencor, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03:00 PM
05-06	Earnings Flash (XNCR) Xencor, Inc. Reports Q1 Revenue $4.5M	MT

Evolution of the Average Target: Xencor, Inc.

Evolution of the Target Price: Xencor, Inc.

Changes in Analyst Recommendations: Xencor, Inc.

b677d6.hTA7CBfazNqCN-FOpxKRh8Wq0HNxvqIVAB0je67kKEQ.z0Nda0SijazrR64X7nDl4vfzmT46h_EiM35GOsKTZQDUWUpDL7KGnclyjg~fa4a20f04465a85da66336eb7cb90ea1

Analysts' recommendations: Xencor, Inc.

03-24	Xencor Shares Fall After JPMorgan Downgrade	MT
03-24	JPMorgan Downgrades Xencor to Neutral From Overweight, Adjusts PT to $13 From $18	MT
11-06	RBC Raises Price Target on Xencor to $19 From $18, Keeps Outperform, Speculative Risk	MT
25-10-29	Xencor Shares Rise After Barclays Upgrade	MT
25-10-29	Barclays Upgrades Xencor to Overweight From Underweight, Adjusts Price Target to $23 From $6	MT
25-10-27	RBC Raises Price Target on Xencor to $18 From $15, Keeps Outperform, Speculative Risk	MT
25-10-24	Xencor, Inc. Presents Initial Data for XmAb819, a First-In-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma	CI
25-10-14	Xencor Shares Fall After Early Commentary on Kidney Cancer Drug Trial Abstract	MT
25-09-03	Xencor Shares Fall After BofA Securities Downgrade	MT
25-09-03	BofA Securities Downgrades Xencor to Neutral From Buy	MT
25-08-21	RBC Cuts Price Target on Xencor to $15 From $32, Keeps Outperform, Speculative Risk	MT
25-08-07	Wedbush Cuts Price Target on Xencor to $26 From $31, Keeps Outperform Rating	MT
25-04-21	William Blair Initiates Xencor at Outperform	MT
25-02-28	RBC Capital Adjusts Xencor Price Target to $32 From $34, Maintains Outperform - Speculative Risk Rating	MT
25-02-28	Wedbush Cuts Price Target on Xencor to $31 From $38, Keeps Outperform Rating	MT
24-12-12	Wells Fargo Initiates Xencor at Overweight With $37 Price Target	MT
24-12-02	Piper Sandler Upgrades Xencor to Overweight, Price Target is $30	MT
24-09-26	RBC Raises Price Target on Xencor to $34 From $31, Keeps Outperform, Speculative Risk	MT
24-06-14	Raymond James Adjusts Price Target on Xencor to $40 From $58, Maintains Strong Buy Rating	MT
24-06-14	BMO Capital Adjusts Xencor's Price Target to $32 From $34, Keeps Outperform Rating	MT
24-06-14	RBC Trims Price Target on Xencor to $31 From $32, Maintains Outperform, Speculative Risk Rating	MT
24-06-13	Wedbush Cuts Price Target on Xencor to $34 From $36, Maintains Outperform Rating	MT
24-05-10	Wedbush Adjusts Xencor's Price Target to $36 From $34, Keeps Outperform Rating	MT
24-04-16	BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating	MT
24-02-28	Wedbush Adjusts Xencor's Price Target to $34 From $36, Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	XENCOR, INC.					+80.81%
	ARGENX SE					+9.17%
	WUXI APPTEC CO., LTD.					+23.98%
	INSMED INCORPORATED					+74.63%
	BIONTECH SE					+29.59%
	WUXI BIOLOGICS (CAYMAN) INC.					+27.19%
	GENMAB A/S					+23.11%
	PHARMAESSENTIA CORPORATION					-24.27%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+6.54%
	EXELIXIS, INC.					-11.75%
	Average					+23.90%
	Weighted average by Cap.					+19.95%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.67USD

Average target price

28.33USD

Spread / Average Target

+80.81%

High Price Target

43.00USD

Spread / Highest target

+174.41%

Low Price Target

14.00USD

Spread / Lowest Target

-10.66%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

JPMorgan Chase
RBC Capital Markets
Barclays
BofA Securities
Wedbush
William Blair & Co.
Wells Fargo Securities
Piper Sandler
Raymond James
BMO Capital
BTIG
Berenberg Bank
Canaccord Genuity
EF Hutton
Cowen
HC Wainwright
SMBC Nikko
Guggenheim
SVB Leerink